mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron

  1. Hye Kyung Lee
  2. Ludwig Knabl
  3. Juan I. Moliva
  4. Ludwig Knabl
  5. Anne P. Werner
  6. Seyhan Boyoglu-Barnum
  7. Sebastian Kapferer
  8. Birgit Pateter
  9. Mary Walter
  10. Nancy J. Sullivan
  11. Priscilla A. Furth
  12. Lothar Hennighausen

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.celrep.2022.110680
  2. ScreenIT

    SciScore for 10.1101/2021.09.08.21263284: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Study population, study design and recruitment: Sixteen COVID-19 recovered volunteers who were infected with SARS-CoV-2 and developed COVID-19 in the spring of 2020 and 14 SARS-CoV-2 naïve healthy volunteers and (Supplementary Table 1) were recruited for the study under informed consent.
    Field Sample Permit: This study was approved (EK Nr: 1064/2021) by the Institutional Review Board (IRB) of the Office of Research Oversight/Regulatory Affairs, Medical University of Innsbruck, Austria, which is responsible for all human research studies conducted in the State of Tyrol (Austria).
    IRB: This study was approved (EK Nr: 1064/2021) by the Institutional Review Board (IRB) of the Office of Research Oversight/Regulatory Affairs, Medical University of Innsbruck, Austria, which is responsible for all human research studies conducted in the State of Tyrol (Austria).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Anti-S binding ELISA: Anti-SARS-CoV-2 S-Protein antibodies were measured using the Roche Elecsys Anti-SARS-CoV-2 S immunoassay on a Cobas e411 analyzer (Roche Diagnostics, Basel, Switzerland) as described somewhere else18.
    Anti-S binding ELISA: Anti-SARS-CoV-2 S-Protein
    suggested: None
    Anti-SARS-CoV-2
    suggested: None
    Software and Algorithms
    SentencesResources
    The raw data were subjected to QC analyses using the FastQC tool (version 0.11.9) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
    FastQC
    suggested: (FastQC, RRID:SCR_014583)
    mRNA-seq read quality control was done using Trimmomatic 19 (version 0.36) and STAR RNA-seq 20 (version STAR 2.5.4a) using 150 bp paired-end mode was used to align the reads (hg19).
    Trimmomatic
    suggested: (Trimmomatic, RRID:SCR_011848)
    STAR
    suggested: (STAR, RRID:SCR_004463)
    HTSeq 21 (version 0.9.1) was to retrieve the raw counts and subsequently, Bioconductor package DESeq2 22 in R (https://www.R-project.org/) was used to normalize the counts across samples and perform differential expression gene analysis.
    HTSeq
    suggested: (HTSeq, RRID:SCR_005514)
    Bioconductor
    suggested: (Bioconductor, RRID:SCR_006442)
    DESeq2
    suggested: (DESeq, RRID:SCR_000154)
    Additionally, the RUVSeq 23 package was applied to remove confounding factors.
    RUVSeq
    suggested: (RUVSeq, RRID:SCR_006263)
    The visualization was done using dplyr (https://CRAN.R-project.org/package=dplyr) and ggplot2 24.
    ggplot2
    suggested: (ggplot2, RRID:SCR_014601)
    P-values of cytokines were calculated using two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli on GraphPad Prism software (version 9.0.0).
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations of this study: This elderly cohort previously infected with SARS-CoV-2 was from a narrowly defined geographically area and included only one gender (females). The infection occurred in the spring of 2020 and the viral strain had not been sequenced. The SARS-CoV-2 antigen-naïve population was from a narrowly defined geographically area. The study was confined to the BNT162b mRNA vaccine.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.09.08.21263284 on medRxiv